Company profile
biopharmaceuticals · Paris, France · sanofi.com
Sanofi is a global biopharmaceutical company focused on medicines and vaccines, with a portfolio spanning immunology, neurology, oncology, rare diseases, vaccines. Its current direction emphasizes pipeline execution, launch performance, broader use of AI and digital tools across R&D, manufacturing, commercial workflows.
Management says innovation is the key driver as the company becomes a fully focused, science-driven biopharma company.
Full year 2024 results said innovation will remain the key driver for launch excellence, 2025 guidance reiterated strong sales and EPS growth.
Sanofi is publicly positioning AI as an operating model, not only a research tool.
The company says it is building on Expert AI, Snackable AI, Generative AI, that 20,000 Sanofians use plai every day.
The company is using AI, machine learning, integrated data platforms to accelerate discovery and trials.
Sanofi says AI helps with target identification, molecule design, clinical data integration, digital biomarkers, it is building scalable data platforms across R&D.
Sanofi uses external partnerships to extend science, digital, platform capabilities.
Public partnerships include AI collaborations for drug development and digital data science partnerships for targets, modules, patient experience.
Sanofi appears to be a cloud aware, data intensive enterprise that is pushing digitized operations, AI enabled workflows, secure third party IT dependencies.
Public filings say core functions depend on cloud based computing and third party providers, while public AI pages stress integrated data platforms, internal AI tools, responsible AI controls.
This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.
Generate a full briefYour first brief is free, no card required.
Evidence confidence 84/100. Generated 2026-07-03 from public sources.